Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance?

JNJ fell 5.8% after its Q3 2026 report, even as the company raised full-year guidance. The reaction shows traders focused on the sales miss rather than the earnings beat.

The split result drove the move: earnings topped expectations, but revenue came in below. The shortfall traces to MedTech, which grew just 2.5%. Management pointed to Abiomed declines and international market challenges as the drags. Innovative Medicine, by contrast, remained strong and carried the quarter.

Management paired the raised guidance with a longer-term target: more than $100 billion in 2026 revenue, with growth expected to accelerate in 2027. Interpretation: the market appears to be discounting the forward targets in favor of near-term top-line softness in a segment that has underperformed, and a 5.8% drop suggests the sales miss carried more weight than the guidance raise.

The setup matters for the medtech peer group, including MDT, ABT, SYK, and BSX. JNJ's MedTech slowdown at 2.5% growth gives traders a reference point when weighing peer results, though the article ties the weakness to JNJ-specific factors like Abiomed rather than to the whole group.